Project Grant R43AG084445
Award Date 8/1/24
Completion Date 7/31/25
Dollars Obligated $505K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Providence, RI 02903, USA
Similar Awards
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $391,850 to support the development of a RUNX1 modulator therapy to slow cognitive decline in Alzheimer's disease (AD). The primary objectives are to: 1) optimize the safety and potency of a RUNX1-targeting antisense oligonucleotide (ASO) development candidate, and 2) demonstrate the efficacy of the RUNX1 ASO in a mouse model of AD using molecular biomarkers and behavioral endpoints. The goal is...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,249,957 Project Grant under CFDA 93.866 (Aging Research) to Advantage Therapeutics, Inc. in Florida. The grant aims to perform IND-enabling studies on a small molecule that is disease-modifying, low-cost, and has a long safety record for the treatment of Alzheimer's disease. The proposed molecule is designed to reduce brain inflammation and restore phagocytosis, thereby improving the...
- This Project Grant award of $475,014.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a novel neurotrophic therapeutic for treating the cognitive deficits associated with Alzheimer's disease. The key products and services to be delivered through this grant include: Scaling up the production of a recombinant, non-erythropoietic neurotrophic protein that has demonstrated cognitive enhancement effects in Alzheimer's disease models. Evaluating the toxicity...
- This federal Project Grant award of $835,417, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to develop novel lipid nanoparticle (LNP) formulations for the delivery of nucleic acid therapeutics to the brain for the treatment of Alzheimer's disease (AD). The key objectives include: 1) synthesizing novel blood-brain barrier (BBB)-crossing lipids, 2) formulating a library of LNPs, and 3) elucidating their trafficking pathways across the BBB. Additionally, the...
- This federal Project Grant award of $238,500 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research conducted by the University of California, San Diego (UCSD) to develop a new phosphorodiamidate morpholino oligonucleotide (PMO) therapeutic for treating Alzheimer's disease (AD). The research aims to create a highly effective PMO that can...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize lead APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying the most promising candidates for further development and evaluation...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,432,649 to Virogenics, Inc., a biotechnology company in San Diego, California, to advance the development of CMS121, an innovative drug candidate for the treatment of Alzheimer's disease (AD). The funding will support two key components: 1) A 13-week toxicology study in rats and dogs to enable longer-term clinical trials of CMS121 in human subjects with mild to moderate AD, and 2) The...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $258,213 to Reelin Therapeutics, Inc. to identify the next generation of gamma-secretase modulators for the treatment of Alzheimer's disease. The research aims to develop novel lead compounds that can lower amyloid-beta 42 production, a key driver of amyloid plaque formation, while avoiding effects on other gamma-secretase substrates like Notch. Through medicinal chemistry and in vitro/in vivo...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...